The Food and Drug Administration has extended approval of dolutegravir tablets for oral suspension to treat HIV in newborns, covering infants weighing at least 2 kilograms from birth up to 4 weeks of age. Until this week, the drug sold as Tivicay PD was approved only for infants 4 weeks and older weighing at least 3 kilograms.
The practical effect is narrow in the United States and significant worldwide. Roughly 4.4 pounds is now the lower weight boundary, and the first four weeks of life are now covered by a label rather than by clinical judgment alone.
For American families, this mostly affects a small number of households: parents whose newborn was exposed to HIV during pregnancy or delivery and who now face decisions in a neonatal unit within hours of birth. A CDC analysis of perinatal HIV counted 32 U.S.-born infants with perinatally acquired HIV in 2019, down from 74 in 2010. The clinicians managing those cases have had unusually few approved options to work with.
Treatment Guidelines Moved Ahead of the Label
The most telling detail in this approval is that specialists were not waiting for it. The federal panel that writes the pediatric HIV treatment guidelines had already endorsed using dolutegravir dispersible tablets in newborns of at least 37 weeks gestational age weighing 2 kilograms or more, based on pharmacokinetic modeling and simulation together with clinical trial data. The same update made dolutegravir the preferred component of initial therapy for full-term infants from birth, paired with a two-drug nucleoside backbone.
That guidance came with an explicit caveat. The panel noted that the dosing strategy "is not currently approved by the FDA," a line that placed treating clinicians in the position of following national expert recommendations while working outside the product label.
Off-label prescribing is legal and common in pediatrics, but it carries real friction. Pharmacies may question the order, institutional protocols may lag, and insurers can push back on coverage for a use not described by the label. An approval does not change the underlying science here. It changes the paperwork, and paperwork often determines whether a newborn gets medicine on schedule.
The gap had a regulatory history. Dolutegravir was first approved for adults in 2013, and the dispersible tablet formulation was approved for infants aged 4 weeks and older in 2020. Extending the label downward to birth required a separate application, which the FDA reviewed under priority designation, as reported after the agency's announcement.
The Newborn Window Where Timing Changes Outcomes
HIV progresses faster in infants than in adults, and the first weeks of life are when that difference is most consequential. According to ViiV Healthcare, the company that makes the drug, roughly half of untreated infants living with HIV die by age two.
Dolutegravir belongs to the class of integrase strand transfer inhibitors and is a second-generation agent with a higher barrier to drug resistance than earlier options. The company says this makes dolutegravir the first second-generation integrase inhibitor available for newborns.
The approval rests on phase 1 data from 48 newborns showing drug levels comparable to those associated with effectiveness in adults, with a safety profile consistent with that seen in older infants and adults. The supporting evidence came from a neonatal dolutegravir dosing study known as IMPAACT 2023, an open-label trial in full-term infants exposed to HIV, together with pharmacokinetic modeling that incorporated additional pediatric data.
That is a small dataset by adult trial standards, and it is worth stating plainly. Effectiveness in this age group was inferred from drug exposure levels rather than demonstrated through a large outcomes trial, which is the standard approach for neonatal drug approvals but still a real limitation.
A Narrow US Population with Global Implications
The United States achieved both of its perinatal HIV elimination targets in 2019, with the transmission rate falling to 0.9 percent. That success is precisely why the number of domestic patients is small.
The global picture is different. More than a million children under 15 are living with HIV worldwide, and pediatric formulations have consistently trailed adult ones by years. A US label extension carries weight beyond American borders because it often anchors regulatory decisions and procurement standards elsewhere. The European Medicines Agency has been reviewing a parallel application for the same neonatal population.
Within the United States, the households most affected are those where a pregnancy involved late HIV diagnosis, a detectable viral load near delivery, or interrupted antiretroviral therapy during pregnancy. Those are the circumstances that place a newborn in the higher risk category, and they cluster among patients facing barriers to consistent prenatal care.
Practical Steps for Pregnant Patients and New Parents
Nothing about this approval changes what prevention looks like. HIV testing during pregnancy remains the single most effective step, because maternal treatment that suppresses viral load sharply reduces the chance of transmission, according to CDC guidance for pregnant people.
Pregnant patients who have not been tested for HIV can request testing at any prenatal visit, at a labor and delivery unit, or through a local health department. Testing is covered at no cost-sharing under most insurance plans and is available for free through many county health departments in major metro areas.
Parents of an infant already on antiretroviral therapy should not adjust anything on their own. Any change to a newborn's regimen should be made in consultation with the pediatric infectious disease team managing the case. Newborn dosing is weight-based and recalculated frequently in the first weeks of life, which is one reason these cases are managed by specialists rather than adjusted at home. Families who encounter an insurance denial for a neonatal antiretroviral can ask the prescribing clinician to reference the updated dolutegravir dosing information, which may resolve a rejection based on the previous age limit.
The next developments to watch are the updated prescribing information reaching pharmacies and the European regulatory decision on the parallel application. Neither has a publicly confirmed date.
Key Questions Answered
What changed with this approval? Tivicay PD, the dispersible tablet form of dolutegravir, can now be used to treat HIV in infants from birth up to 4 weeks who weigh at least 2 kilograms. Previously, the drug was approved only from 4 weeks of age at 3 kilograms or more.
Were newborns receiving this medicine before the approval? Yes. The federal pediatric HIV treatment guidelines already supported this use based on pharmacokinetic modeling and clinical trial data, while noting the dosing strategy was not FDA-approved at the time.
How many US newborns does this affect? A small number. A CDC analysis counted 32 US-born infants with perinatally acquired HIV in 2019, following sustained declines in perinatal transmission.
What evidence supported the decision? Phase 1 data from 48 newborns showed drug levels similar to those associated with effectiveness in adults, with a safety profile consistent with that observed in older infants and adults. Data came from the IMPAACT 2023 study plus pharmacokinetic modeling.
Does this reduce the risk of a baby acquiring HIV? No. This is a treatment approval, not a prevention measure. Maternal testing and effective antiretroviral therapy during pregnancy remain the primary way to prevent transmission.
Where can a pregnant person get HIV testing? Prenatal clinics, labor and delivery units, and county health departments all offer testing. Most insurance plans cover it without cost sharing, and many local health departments provide it at no charge.
What happens next? Updated prescribing information will reach pharmacies, and the European Medicines Agency continues reviewing a parallel application for the same neonatal population. No decision date has been made public.
